piflufolastat (18F)
- Generic Name
- piflufolastat (18F)
Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC
Phase 1
Not yet recruiting
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 228
- Registration Number
- NCT06881823
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Phase 4
Recruiting
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Blue Earth Diagnostics
- Target Recruit Count
- 52
- Registration Number
- NCT06604442
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸Tower Urology, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath